Resources
88 Results (showing 51 - 60)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 7/7/2021 (updated 4/2/2024)
This presentation highlighted the intersection of discrimination, women, substance use and reproductive rights from historical and current perspectives. It then provided methods and techniques for eliminating stigma and discrimination on a provider-patient level and provide an opportunity for the audience to practice compassionate care.
Posted 7/21/2021 (updated 4/2/2024)
Goals: Increase knowledge of harm reduction principles, strategies, and resources, increase knowledge of managed use, abstinence, and safer use to meet people who use drugs where they are at, provide a safe environment (plenaries and breakouts) to discuss licit and illicit drug use as a multi-faceted phenomenon requiring successful interventions and policies and increase knowledge of stigma as it relates to harm reduction principles and practices.
Expanding The Circle of Care: A Practical Guide to Syringe Services for Tribal and Rural Communities
Posted 8/3/2021 (updated 4/2/2024)
This guide presents practical information on establishing and maintaining syringe services in rural and tribal communities based on experiences of the Bad River Band of Lake Superior Chippewa.
Posted 8/4/2021 (updated 4/2/2024)
Adverse childhood experiences, known as ACEs, are defined by the Centers for Disease Control and Prevention as "potentially traumatic events that occur in childhood." One common example is experienced by children growing up in a household with parents engaged in substance use. This publication is the first in a two-part series addressing the relationship between ACEs and substance use throughout the life cycle, covering substance use as an ACE from infancy through adolescence.
Posted 8/4/2021 (updated 4/2/2024)
Posted 8/19/2021 (updated 4/2/2024)
In spring 2021, pharmaceutical manufacturers and distributors notified syringe services programs (SSPs) and partners that there would be significant interruptions in the supply of injectable/intramuscular (IM) naloxone. Currently, production and distribution delays are expected to last until fall 2021. This will specifically affect SSPs because IM naloxone is the most affordable formulation, and therefore is most commonly utilized by programs that distribute large volumes of naloxone to reduce fatal overdose rates.
Posted 9/1/2021 (updated 4/2/2024)
Posted 9/1/2021 (updated 4/2/2024)
Posted 9/1/2021 (updated 4/2/2024)
Posted 11/4/2020 (updated 4/3/2024)
The opioid crisis has disproportionally affected Appalachia. One of the potentially
lethal and costly complications associated with IV drug use is infective endocarditis (IE). The goal of this study was to assess the trend and costs of substance abuse associated IE admissions in Southern West Virginia.